Table 2.
Baseline laboratory and radiologic findings of the study population.
| n (%) | |||
|---|---|---|---|
| Total (n = 30) | Sarilumab + SC (n = 20) | SC (n = 10) | |
| Laboratory values (median, IQR) | |||
| White Blood Count (cells/mm3) | 7,985 (5,160–11,140) | 7,070 (4,975–12,310) | 10,065 (6,750–10,460) |
| Lymphocyte Count (cells/mm3) | 830 (680–1,130) | 825 (680–1,070) | 865 (680–1,580) |
| Neutrophil Count (cells/mm3) | 5,910 (3,935–9,312) | 6,215 (5,398–9,313) | 5,850 (3,575–10,972) |
| Creatinine. mg/dL | 0.80 (0.63–0.98) | 0.83 (0.71–0.99) | 0.65 (0.59–0.87) |
| Bilirubin. mg/dL | 0.40 (0.32–0.52) | 0.38 (0.32–0.53) | 0.49 (0.34–0.52) |
| AST. U/L | 33 (26-54) | 40 (27-53) | 32 (25-93) |
| ALT. U/L | 46 (24-61) | 48 (29-57) | 28 (21-97) |
| GGT. U/L | 56 (34-117) | 41 (30-119) | 71 (55–108) |
| LDH. U/L | 297 (238–349) | 317 (263–350) | 263 (222–333) |
| Inflammatory markers | |||
| serum IL-6. pg/mL (n = 24) | 12 (3–21.5) | 13.3 (7.5–24) | 3 (1–16.5) |
| IL-6 ≥ 30 pg/mL, n (%) | 4/24 (17) | 3/16 (19) | 1/8 (13) |
| Ferritin. ng/mL (n = 29) | 1,179 (735–1,511) | 1,048 (664–1,511) | 1,265 (735–1,532) |
| CRP. mg/dL | 9.28 (5.06–19.73) | 8.59 (4.17–18.1) | 9.94 (6.19–19.73) |
| PCT. ng/mL (n = 13) | 0.11 (0.08–0.18) | 0.11 (0.09–0.18) | 0.12 (0.07–0.18) |
| D-dimer (μg/mL) (n = 29) | 0.49 (0.37–1.14) | 0.49 (0.36–1.28) | 0.51 (0.37–1.09) |
| Baseline thorax radiologic findings (x ray and/or CT scan) a | |||
| Alveolar pattern or ground glass opacities > 50% | 14 (47) | 11 (55) | 3 (30) |
AST, Aspartate amino-transferase; ALT, Alanine amino- transferase; CRP, C-reactive protein; GGT, Gamma-glutamyl transferase; IL-6, Interleukin-6; IQR, Interquartile range; LDH, Lactate Dehydrogenase; PCT, Procalcitonin. SC, Standard care.
a
All radiologic exams were assessed and reported by radiologists with pneumological expertise.